Adam M Sonabend

List of Publications by Year
in descending order

72	2,925	186265 28	189892 50
papers	citations	h-index	g-index

79	79	79	4587
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nature Medicine, 2019, 25, 462-469.	30.7	569
2	Mesenchymal Stem Cells Effectively Deliver an Oncolytic Adenovirus to Intracranial Glioma. Stem Cells, 2008, 26, 831-841.	3.2	226
3	A first-in-human phase 0 clinical study of RNA interferenceâ€“based spherical nucleic acids in patients with recurrent glioblastoma. Science Translational Medicine, 2021, 13, .	12.4	136
4	Glioblastoma Models Reveal the Connection between Adult Glial Progenitors and the Proneural Phenotype. PLoS ONE, 2011, 6, e20041.	2.5	129
5	Prevention of Ventriculostomy-Related Infections With Prophylactic Antibiotics and Antibiotic-Coated External Ventricular Drains: A Systematic Review. Neurosurgery, 2011, 68, 996-1005.	1.1	110
6	Frailty in Geriatric Glioblastoma Patients: A Predictor of Operative Morbidity and Outcome. World Neurosurgery, 2016, 89, 362-367.	1.3	98
7	Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor Formulations. Clinical Cancer Research, 2020, 26, 477-486.	7.0	98
8	Quantitative assessment of protein activity in orphan tissues and single cells using the metaVIPER algorithm. Nature Communications, 2018, 9, 1471.	12.8	95
9	Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial. Lancet Oncology, The, 2021, 22, 1103-1114.	10.7	91
10	Invasion and proliferation kinetics in enhancing gliomas predict IDH1 mutation status. Neuro-Oncology, 2014, 16, 779-786.	1.2	77
11	Antiâ€“PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells. Clinical Cancer Research, 2020, 26, 4699-4712.	7.0	65
12	Microsurgical resection of pineal region tumors. Journal of Neuro-Oncology, 2016, 130, 351-366.	2.9	63
13	Solitary-fibrous tumor/hemangiopericytoma of the central nervous system: a population-based study. Journal of Neuro-Oncology, 2018, 138, 173-182.	2.9	59
14	Prolonged intracerebral convection-enhanced delivery of topotecan with a subcutaneously implantable infusion pump. Neuro-Oncology, 2011, 13, 886-893.	1.2	56
15	The Transcriptional Regulatory Network of Proneural Glioma Determines the Genetic Alterations Selected during Tumor Progression. Cancer Research, 2014, 74, 1440-1451.	0.9	48
16	Craniotomy and Survival for Primary Central Nervous System Lymphoma. Neurosurgery, 2019, 84, 935-944.	1.1	46
17	Extent of resection and survival for oligodendroglioma: a U.S. population-based study. Journal of Neuro-Oncology, 2019, 144, 591-601.	2.9	45
18	The Safety of Surgery in Elderly Patients with Primary and Recurrent Glioblastoma. World Neurosurgery, 2015, 84, 913-919.	1.3	44

#	Article	IF	Citations
19	Activation of 4-1BBL+ B cells with CD40 agonism and IFNÎ³ elicits potent immunity against glioblastoma. Journal of Experimental Medicine, 2021, 218, .	8.5	42
20	Newly Diagnosed Glioblastoma: A Review on Clinical Management. Oncology, 2019, 33, 91-100.	0.5	42
21	ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. Nature Cancer, 2021, 2, 1372-1386.	13.2	39
22	Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma. Clinical Cancer Research, 2021, 27, 1766-1777.	7.0	38
23	Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy. Neuro-Oncology, 2020, 22, 1425-1438.	1.2	37
24	Murine cell line model of proneural glioma for evaluation of anti-tumor therapies. Journal of Neuro-Oncology, 2013, 112, 375-382.	2.9	36
25	CD8+ T-cellâ€“Mediated Immunoediting Influences Genomic Evolution and Immune Evasion in Murine Gliomas. Clinical Cancer Research, 2020, 26, 4390-4401.	7.0	36
26	The possibility of cancer immune editing in gliomas. A critical review. OncoImmunology, 2018, 7, e1445458.	4.6	35
27	Convection-enhanced delivery of etoposide is effective against murine proneural glioblastoma. Neuro-Oncology, 2014, 16, 1210-1219.	1.2	34
28	Defining Glioblastoma Resectability Through the Wisdom of the Crowd: A Proof-of-Principle Study. Neurosurgery, 2017, 80, 590-601.	1.1	34
29	Extent of resection, molecular signature, and survival in 1p19q-codeleted gliomas. Journal of Neurosurgery, 2021, 134, 1357-1367.	1.6	31
30	A phase 0 first-in-human study using NU-0129: A gold base spherical nucleic acid (SNA) nanoconjugate targeting BCL2L12 in recurrent glioblastoma patients.. Journal of Clinical Oncology, 2019, 37, 3012-3012.	1.6	30
31	Timing and risks of chemoprophylaxis after spinal surgery: a single-center experience with 6869 consecutive patients. Journal of Neurosurgery: Spine, 2017, 27, 681-693.	1.7	28
32	The safety of resection for primary central nervous system lymphoma: a single institution retrospective analysis. Journal of Neuro-Oncology, 2017, 132, 189-197.	2.9	25
33	Ribosomal protein S11 influences glioma response to TOP2 poisons. Oncogene, 2020, 39, 5068-5081.	5.9	21
34	LTBK-04. PHASE 2 MULTICENTER STUDY OF THE ONCOLYTIC ADENOVIRUS DNX-2401 (TASADENOTUREV) IN COMBINATION WITH PEMBROLIZUMAB FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192). Neuro-Oncology, 2020, 22, ii237-ii237.	1.2	21
35	Online Ratings of Neurosurgeons. Neurosurgery, 2018, 83, 1143-1152.	1.1	19
36	Primary Central Nervous System Lymphoma: A Critical Review of the Role of Surgery for Resection. Archives in Cancer Research, 2016, 4, .	0.3	18

#	Article	IF	Citations
37	Topoisomerase II Poisons for Glioblastoma; Existing Challenges and Opportunities to Personalize Therapy. Frontiers in Neurology, 2018, 9, 459.	2.4	18
38	Overcoming the Bloodâ€“Brain Barrier with an Implantable Ultrasound Device. Clinical Cancer Research, 2019, 25, 3750-3752.	7.0	18
39	Breast cancer subtype and stage are prognostic of time from breast cancer diagnosis to brain metastasis development. Journal of Neuro-Oncology, 2017, 134, 453-463.	2.9	16
40	Predictors of Readmissions and Reoperations Related to Venous Thromboembolic Events After Spine Surgery: A Single-Institution Experience with 6869 Patients. World Neurosurgery, 2018, 111, e91-e97.	1.3	16
41	Monitoring Radiation Treatment Effects in Glioblastoma: FLAIR Volume as Significant Predictor of Survival. Tomography, 2017, 3, 131-137.	1.8	15
42	Invasiveness is associated with metastasis and decreased survival in hemangiopericytoma of the central nervous system. Journal of Neuro-Oncology, 2017, 133, 409-417.	2.9	14
43	Spinal location is prognostic of survival for solitary-fibrous tumor/hemangiopericytoma of the central nervous system. Journal of Neuro-Oncology, 2019, 143, 457-464.	2.9	14
44	Role of Resection in Glioblastoma Management. Neurosurgery Clinics of North America, 2021, 32, 9-22.	1.7	14
45	The Eclectic Nature of Glioma-Infiltrating Macrophages and Microglia. International Journal of Molecular Sciences, 2021, 22, 13382.	4.1	14
46	Assessing the Safety of Craniotomy for Resection of Primary Central Nervous System Lymphoma: A Nationwide Inpatient Sample Analysis. Frontiers in Neurology, 2017, 8, 478.	2.4	13
47	Risk Factors for Transverse Ligament Disruption and Vertebral Artery Injury Following an Atlas Fracture. World Neurosurgery, 2021, 146, e1345-e1350.	1.3	12
48	Quality Assessment of Stereotactic Radiosurgery of a Melanoma Brain Metastases Model Using a Mouselike Phantom and the Small Animal Radiation Research Platform. International Journal of Radiation Oncology Biology Physics, 2017, 99, 191-201.	0.8	11
49	Immunotherapy Against Gliomas: is the Breakthrough Near?. Drugs, 2019, 79, 1839-1848.	10.9	10
50	Surgery plus adjuvant radiotherapy for primary central nervous system lymphoma. British Journal of Neurosurgery, 2020, 34, 690-696.	0.8	10
51	Can patient selection and neoadjuvant administration resuscitate PD-1 inhibitors for glioblastoma?. Journal of Neurosurgery, 2020, 132, 1667-1672.	1.6	10
52	Single institution validation of a modified graded prognostic assessment of patients with breast cancer brain metastases. CNS Oncology, 2018, 7, 25-34.	3.0	9
53	Uncertainty in the Relationship Between Sagittal Alignment and Patient-Reported Outcomes. Neurosurgery, 2020, 86, 485-491.	1.1	9
54	Trends in national utilization of posterior lumbar fusion and 30-day reoperation and readmission rates from 2006â€“2016. Clinical Neurology and Neurosurgery, 2020, 199, 106310.	1.4	8

#	Article	IF	Citations
55	Delivering albumin-bound paclitaxel across the blood-brain barrier for gliomas. Oncotarget, 2021, 12, 2474-2475.	1.8	6
56	Ultrasound-mediated Blood-brain barrier opening increases cell-free DNA in a time dependent manner. Neuro-Oncology Advances, 2021, 3, vdab165.	0.7	5
57	The role of preoperative embolization in the treatment of spinal metastases from renal cell carcinoma. Clinical Neurology and Neurosurgery, 2022, 215, 107181.	1.4	5
58	TOP2B Enzymatic Activity on Promoters and Introns Modulates Multiple Oncogenes in Human Gliomas. Clinical Cancer Research, 2021, 27, 5669-5680.	7.0	4
59	Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma. Clinical Cancer Research, 2022, 28, 3156-3169.	7.0	4
60	Myeloid Cell Classification and Therapeutic Opportunities Within the Glioblastoma Tumor Microenvironment in the Single Cell-Omics Era. Frontiers in Immunology, 0, 13, .	4.8	4
61	Management Paradigms Along a Histologic Spectrum of Pineal Cell Tumors. World Neurosurgery, 2014, 81, 685-687.	1.3	3
62	Venous air embolus during scalp incision. Journal of Clinical Neuroscience, 2016, 28, 170-171.	1.5	3
63	Evaluation of patient education materials for stereotactic radiosurgery from high-performing neurosurgery hospitals and professional societies. Neuro-Oncology Practice, 2020, 7, 59-67.	1.6	3
64	Newly diagnosed enhancing lesions: Steroid initiation may impede diagnosis of lymphoma involving the central nervous system. Journal of Clinical Neuroscience, 2020, 81, 61-64.	1.5	3
65	Management of glioblastoma: a perspective from Mexico. Chinese Clinical Oncology, 2021, 10, 1-1.	1.2	2
66	Glioma immunoediting, a driver of tumor evolution, and the next battle for immunotherapy. Oncotarget, 2021, 12, 8-9.	1.8	2
67	Boosting Dendritic Cell Vaccination for Glioblastoma Using Tetanus Toxoid. Neurosurgery, 2015, 77, N20-N21.	1.1	0
68	Outcomes of thoracic discectomy: A single center retrospective series. Journal of Clinical Neuroscience, 2018, 48, 128-132.	1.5	0
69	Immunopathology and Immunotherapy of Central Nervous System Cancer. , 2020, , 379-425.		0
70	BIOM-31. ERK1/2 PHOSPHORYLATION PREDICTS SURVIVAL FOLLOWING ANTI-PD-1 IMMUNOTHERAPY IN RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi17-vi17.	1.2	0
71	BIOM-32. ENDOPLASMIC RETICULUM PROTEIN SSR3 DETERMINES AND PREDICTS RESPONSE TO PACLITAXEL IN BREAST CANCER AND GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi17-vi18.	1.2	0
72	Abstract 2548: The central nervous system immune cell interactome is a function of cancer lineage, tumor microenvironment and STAT3 expression. Cancer Research, 2022, 82, 2548-2548.	0.9	0